Abstract:
The existence of specific cellular subpopulations within primary tumors with increased tumorigenic potential and chemotherapy resistance (tumor-initiating cells, TICs) holds great therapeutic implications. Resistant cells can remain quiescent for long periods and be responsible for local relapses and metastasis. We and others have previously described in non-small-cell lung cancer the presence of cisplatin-resistant CD133 + cells with tumor-initiating potential and co-expression of CXCR4 as possible indicator of TICs with disseminating potential. In this study, we report, by in vitro cell fate tracing systems, heterogeneity within the TIC compartment with a highly quiescent pool and a slowly dividing subpopulation, both containing CD133 + cells but respectively enriched for CD133 N on-small-cell lung cancer (NSCLC), representing approximately 80% of all lung cancers, is the main cause of cancer-related deaths worldwide. Even though recently developed targeted therapies have been shown to provide some benefit in predefined subclasses of patients with tumors carrying specific mutations, platinum-based chemotherapy still represent the standard systemic treatment for NSCLC. However, 5-year survival rates have not raised substantially in the past decades, remaining as low as 20% for late stage disease (III-IV). 1 Cisplatin resistance is the consequence of a multifactorial event which involves a combination of features, such as drug inactivation by detoxifying factors, alterations in checkpoint and apoptotic proteins, and variation in intracellular drug accumulation. [2] [3] [4] However a rising number of observations also indicates that, in several tumor types, distinct cellular subpopulations persist after treatment and that these cells own intrinsic characteristics associated with a stem-like phenotype 5 and can be indicated as cancer stem cells or tumor-initiating cells (TICs). TICs characterized by increased tumorigenicity, self-renewal ability, and multipotency 6, 7 have been described for several tumor types, such as myeloid leukemia, 8 glioblastoma, 9-11 melanoma, 12 and several epithelial cancers [13] [14] [15] [16] [17] [18] including lung cancer. 19, 20 Particularly, lung cancer TICs are detected by the expression of cell surface markers as CD133 or by the high activity of aldehyde dehydrogenase and finally by increased capacity to efflux the DNA-binding dye Hoechst 33342 that define the so-called side population cells. 21 22 Furthermore, the stem-like and tumorigenic phenotype has been associated to a slow proliferating fraction of cells within primary lines or cancer cells. 23, 24 The peculiar characteristics of TICs, and in particular their capability to remain in a quiescent state, 25 are consistent with a lower susceptibility to replicationrelated drugs as previously described also in NSCLC, where CD133 + TICs have been reported as being spared by Cisplatin treatment. 20 Moreover, in vitro CDDP treatment of NSCLCderived spheres enriched for TICs induces a replication block (G2/M) and a more efficient DNA damage repair that can be prevented by treatment with inhibitor of checkpoint protein kinase (Chk1). 26 Recently, cancer stem cells (CSC) from NSCLC have also been shown to be susceptible to Bcl-XL inhibition indicating potential therapeutic strategies targeting TICs. 27 We reasoned that an efficient strategy to target TICs could also rely on their mobilization from the quiescence state inducing a chemo-susceptible phenotype, as already proposed and substantiated for leukemic stem cells. 28, 29 Altogether, this would deplete the tumor of its CSCs reservoir preventing relapse, metastasis formation and, eventually, increasing the efficacy of chemotherapy.
In this study, to overcome CDDP resistance of CD133
+ NSCLC CSCs, we tested the capacity of all-trans retinoic acid (ATRA), in vitro and in vivo, to force the TICs fraction to differentiate to a more CDDP susceptible phenotype. ATRA has been reported to be effective in the cure and prevention of many types of cancer (reviewed in 30 ), however, its differentiating role against solid tumors CSC's compartment is still poorly explored. [31] [32] [33] Using in vitro cell fate tracing systems and in vivo models of patient-derived xenografts (PDXs), 34 we show here that ATRA is able to interfere with the dynamics of the CSC compartment and prevents chemotherapy-related TICs increase.
MATERIALS AND METHODS

Cell Cultures
LT73 cells were derived in our laboratory from a primary lung tumor of a 68-year-old Caucasian male patient with lung adenocarcinoma. Cells were grown in RPMI-1640 (Lonza, Basel, Switzerland), supplemented with 10% fetal bovine serum (Lonza) and penicillin/streptomycin (Invitrogen, Carlsbad, CA) at 37°C with 5% CO 2 .
PKH Labeling
LT73 cells were labeled with PKH67 Fluorescent cell linker (Sigma-Aldrich, St. Louis, MO) according to the manufacturer's instruction. In brief, cells were incubated 5 minutes at room temperature with PKH67 Dye Solution. Staining was stopped adding fetal bovine serum (Lonza) and labeled cells were analyzed by flow cytometry at different time points.
Culture of Cancer Tissue-Originated Spheroids
Cancer tissue-originated spheroids (CTOS) culture method was adapted from Kondo et al. 35 In brief, tumor tissue was mechanically and then enzymatically digested in a solution of collagenase IV (5 mg/ml) and DNAse (100 U/ml; Sigma Aldrich, St. Louis, MO) in DMEM/F12 (Lonza, Verviers, Belgium) for 1 hour at 37°C and subsequently filtered through 100-μm and 40-μm cell strainers (Becton Dickinson, Franklin Lakes, NJ). The tumor tissue organoids retained in the strainer were washed in 30 ml of DMEM/F12 and centrifuged at 100g for 5 minutes. Tumor organoids were plated in stem cell medium SCM (described in 20 ) and in 60 mm Petri dishes. Spheroids appeared in about 3 days. For culture expansion, spheroids were centrifuged at 100g for 5 minutes and incubated with a mild digestion solution of DMEM/F12 + collagenase IV 5 mg/ml at 37°C for 5 minutes.
Flow Cytometry Analysis
Single-cell suspensions were washed and incubated in staining solution containing 1% BSA and 2 mM ethylenediaminetetraacetic acid with specific antibodies at appropriate dilutions. For CD133 and CXCR4 staining, 10 6 cells were incubated with phycoerythrin-conjugated anti-CD133/1 (Miltenyi Biotec, Bergish Gladbach, Germany) and allophycocyanin-conjugated anti-CXCR4 (Becton Dickinson). Samples were acquired by FACS Calibur and analyzed with FlowJo_V10 software.
For lung dissemination analysis, a morphological gate allowing the identification of the highest percentage of human tumor cells in murine lungs was identified 36 and subsequent exclusion for 7-AAD + dead cells and mouse H2K + cells was performed. This method was able to specifically detect as few as 10 3 single tumor cells in murine lungs.
Patient-Derived Xenograft Tumor Growth
All experiments were carried out with female SCID mice, 7-10 weeks old (Charles River Laboratories, Calco, Italy). Mice were maintained in laminar flow rooms, with constant temperature and humidity. Mice had free access to food and water. Experiments were approved by the Ethics Committee for Animal Experimentation of the Fondazione IRCCS Istituto Nazionale dei Tumori, according to institutional guidelines. PDXs were established as described.
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PDX111 (EGFRwt, KRASwt, LKB1wt, HER2wt, PIK3wt, BRAFwt) and PDX73 (EGFRwt, KRASwt, LKB1 K287X , HER2wt, PIK3wt, BRAFwt) were derived from a 77-year-old female and a 68-year-old Caucasian male patient, respectively, both with lung adenocarcinoma. For pharmacological experiments, mice were randomly distributed into equal groups (five mice per group, grafted in both flanks). Mice were treated with All-Trans Retinoic Acid (Sigma-Aldrich; 10 mg/kg gavage, qd × 5 × 3 weeks) and/or with Cisplatin (Teva, Petach Tikva, Israel; 5 mg/kg i.v. q7d × 3). 
Statistical Analysis
All data are shown as mean value ± standard error. t tests and Fisher exact test have been performed with GraphPad Prism 4 Software. p values are represented as follows: *: p < 0.05; **: p < 0.01, ***: p < 0.001.
RESULTS
Identification of a Slow Proliferating Fraction of NSCLC Cells Enriched for CD133 + TICs with High In Vivo Tumorigenic Potential
To investigate the compartment of slow proliferating cells and its dynamics in NSCLC, we exploited a general cell membrane labeling system (Fluorescent Cell Linker Kit PKH67, Sigma-Aldrich, St. Louis, MO), previously reported as a useful tool to identify slow proliferating cells 37, 38 because the labeling is progressively diluted through repeated cell divisions whereas not proliferating cells maintain it for weeks. LT73 primary cell line, established from patient's lung adenocarcinoma, was labeled with PKH67 and label retaining was monitored by flow cytometry during serial population doublings (PD). After 10 PDs (PD10) a small amount of labeled cells (PKH + ) was still appreciable (0.22 ± 0.11%, n = 5 replicates) as confirmed also by immunofluorescence analysis ( + cells (400-fold average: 48.3 ± 7.7 versus 0.12 ± 0.05 in total population, n = 5 replicates). We previously demonstrated that CD133 + cells spared by CDDP were particularly enriched for the subset co-expressing the chemokine receptor CXCR4 20 that could be involved in dissemination of TICs. 36, 39 Interestingly, the observed heterogeneity within the slow proliferating PKH + cells is mirrored by different distribution of CXCR4 co-expressing cells, indeed PKH BRIGHT Fig. 2A and PDX73, Fig. 2B ) were stained with PKH67 and reinjected subcutaneously in the flank of immunocompromised mice. In tumors analyzed at different volumes (V 1 = 250 mm 3 , V 2 = 1000 mm 3 ), a small fraction of PKH-labeled cells was still detectable and showed an enrichment of CD133 + TICs (three-to 50-fold depending on the model, Fig. 2 
CDDP-Resistant Subpopulation is Highly Enriched in Slow Proliferating CD133 + Cells
To further demonstrate the link between quiescence and chemoresistance, LT73PKH (PD10) cells were treated with 10 µM CDDP (LD50) for 72 hours. The PKH-positive fraction showed resistance to CDDP treatment, increasing by a 15-fold average enrichment (n = 5 replicates; 2.7 ± 0.7% compared with 0. 22 To verify the effect of differentiating agent on TICs subset, LT73 cell line was treated in vitro with ATRA 10 µM (every 48 hours, from PD8 to PD10); no effect on cell proliferation and viability was observed during treatment (Supplementary 3A, SDC 1, http://links.lww.com/JTO/A843), and a general decrease in CD133 + percentages was induced, even though the only significant effect was observed within PKH CDDP treatment in cells previously exposed to ATRA led to a less pronounced increase of PKH + cells compared with CDDP-only treated cells (1.8 ± 0.85% versus 2.7 ± 0.7% in CDDP-only treated, corresponding to an average prevention of 36.3% of CDDP-induced enrichment, n = 5, Fig. 3A) . In details, ATRA pretreatment was able to prevent increase of CD133 + cells due to CDDP exposure, completely in the PKH NEG fraction and partially in the PKH DIM fraction, without affecting the more quiescent PKH BRIGHT fraction (Fig. 3B and Supplementary Table 1, SDC 2, http://links.lww.com/ JTO/A844). These in vitro data suggest that the differentiating agent is able to sensitize proliferating PKH NEG CD133 + cells to CDDP and is also partially able to push a fraction of quiescent PKH DIM CD133 + into a cisplatin responsive state, seemingly acting on CD133 + /CXCR4 + cells, whose increase is totally prevented. The same experiment was carried out on ex vivo CTOS established from two PDX models. Similarly to in vitro results, ATRA treatment induced a slight decrease of TICs (from 22% to 19%, corresponding to a 14% decrease compared with untreated CTOS111, whereas a higher effect was appreciable in CTOS73, from 0.4% to 0.05%, corresponding to a 87.5% decrease compared with untreated) associated with a down regulation of stemness genes (Supplementary 3B-D, SDC 1, http://links.lww.com/JTO/A843). Moreover, CD133 + cells enrichment after CDDP treatment was partially prevented by ATRA also in these ex vivo models (from 29% to 25% corresponding to a prevention of 57% of CDDP-induced enrichment in CTOS111, and from 0.8% to 0.5% corresponding to a prevention of 75% of CDDP-induced enrichment in CTOS73, Fig. 3C ). Taken together, these in vitro and ex vivo data indicate that within the TIC compartment the differentiating treatment preferentially sensitizes PKH DIM BRIGHT100 and PKH DIM1000 fractions (N = number of tumors; cells = estimated number of injected cells, BRIGHT100: 100 PKH BRIGHT -sorted cells; DIM100/1000: 100/1000 PKH DIM -sorted cells).
FIGURE 2.
The slow proliferating fraction is appreciable also ex vivo in NSCLC PDX. Cells derived from disaggregation of PDX were PKH labeled and reinjected subcutaneously in SCID mice (n = 4). PKH retaining CD133 + enriched cells are appreciable in tumors analyzed at different volumes (V 1 = 250 mm 3 , V 2 = 1000 mm 3 ) in both PDX tested; PDX111 (A) and PDX73 (B).
In Vivo Differentiation Therapy Partially Depletes CD133 + TICs, Leading to a Reduced Tumor Regrowth after Cisplatin Treatment
To investigate if ATRA-driven mobilization of a specific TICs compartment was also effective in vivo, we treated two NSCLC PDXs models (PDX73 and PDX111). ATRA alone slightly decreased the percentage of CD133 + cells (Supplementary 3D, SDC 1, http://links.lww.com/JTO/A843) without affecting tumor growth (Fig. 4A) . Moreover, in both models, the combination of ATRA and CDDP had no synergistic effect on tumor growth, but CD133 + enrichment due to CDDP treatment was strongly counteracted by combined treatment in PDX73 (prevention of 100% of the CDDP-induced enrichment) and partially in PDX111 (prevention of 30% of the CDDP-induced enrichment, Fig. 4A ). Interestingly, in both models, effects of combination therapy were mostly linked to a variation in the CD133 + /CXCR4
+ fraction (prevention of 40% of the CDDP-induced enrichment in PDX73 and of 125% in PDX111, Fig. 4B ). This effect was mirrored by a decreased dissemination of human cells to lungs in mice receiving ATRA pretreatment (Fig. 4B) . On the other hand, CD133 
Multiple Cycles of In Vivo ATRA and CDDP Treatment Significantly Reduce Tumor Volume
To investigate if the effects of the double treatment in vivo were permanent after multiple treatment cycles and to achieve a progressive exhaustion of the TICs reservoir, a serial transplantation experiment was performed. PDX111 residual tumors after treatment were cut in small pieces (3 mm), injected subcutaneously in a set of new mice and treated with ATRA and/or CDDP. After four serial transplantations (S4), a significant decrease in tumor growth of double treated mice compared with CDDP treated counterpart was achieved (V = 467 ± 160 mm 3 and 864 ± 252 in double-treated and CDDP-treated, respectively, Fig. 5A ). This difference in tumor growth was anticipated (at S3) by a lower percentage of CD133 + cells (3.8 ± 0.9% and 13 ± 1.32% in double-treated and CDDP-treated, respectively, Fig. 5A ), which is mainly ascribed to the reduction of CD133 + /CXCR4 + subset. After five treatment cycles, the effects of double treatment on tumor growth were still appreciable with a decrease of tumor volume in double-treated PDX. Interestingly, CD133 + /CXCR4 + cell levels remained low at each cycle of differentiating therapy and this resulted in an appreciable and long-lasting (up to five serial transplants) decrease of disseminating cells in lungs of mice carrying PDXs (Fig. 5C ). When double-treated tumors were transplanted into new mice and not retreated, a progressive increase in tumor growth was observable (Fig. 5B) 
DISCUSSION
TICs have been described in many tumor types for specific features, such as potential to initiate and maintain tumor growth and to give rise to all observed heterogeneous lineages, high expression of stem-related genes and of xenobiotic transporter, and quiescence. These peculiar features suggest them as the prime suspect for tumor relapse or metastasis formation after chemotherapeutical treatment. We previously reported the presence of a cisplatin-resistant CD133 + cellular subpopulation with stem-like characteristics in NSCLC cell lines and in vivo xenograft models. The dynamics of CSCs compartment are beginning to be unraveled in the better understood leukemia models where hierarchy appears more delineated, 29 whereas little is known of this complexity in solid cancers. 40 However, resistance of CSC has already been reported to be linked to a slow rate of proliferation in ovarian, 41 breast, 42 and pancreatic 43 cancer models and here, we demonstrated that the CD133 + residual fraction after CDDP treatment is mainly composed by slow proliferating label-(PKH67) retaining cells. The purpose of this study was to counteract the cisplatin resistance of CD133 + cells, inducing a mobilization of these TICs to a less resistant phenotype using ATRA. ATRA was the first differentiation agent found to be successful in the treatment of acute promyelocytic leukemia where it promotes differentiation of promyelocytic to myeloid cells, blocked by the chimeric protein product of the fusion gene PML/RARα. 44 Retinoic acid has been reported to be involved in processes of lung embryogenesis with an accumulation within the lung during organ development and a temporally association with the process of alveolar septation. The importance of retinoids in the generation of alveoli is confirmed by studies involving retinoid receptor knock-out animals 45 as well as by in vitro experiments on human cell lines demonstrating that retinoic acid can regulate an array of cellular and molecular pathways in lung remodeling. 46 Moreover, a randomized phase II trial indicated that adding ATRA to chemotherapy could increase response rate and progression-free survival in patients with advanced (IIIb-IV) NSCLC. 47 On the basis of these data, we hypothesized that a differentiating therapy with retinoids could play a role in lung tumor growth, promoting the differentiation to a CDDP susceptible state of CD133 + NSCLC TICs. A partial reversion of CDDP-induced enrichment of CD133 + cells in vitro 48 and as a marker for lymph node metastasis in colon cancer models. 49 Moreover, the functional role of CXCR4/CXLC12 axis in cell mobilization, dissemination, and metastasis formation has already been elucidated. 50 Based on PKH retaining ability, we can hypothesize a precise hierarchy within CD133 -cells are represented at high purity (representing more than 30% of the fraction), whereas in the PKH DIM the same number of CD133 + /CXCR4 − cells is contained within a higher number of non-TICs. It is therefore also possible that interference of non-TICs with TICs in the early phases of tumor initiation could be responsible for the delayed and decreased tumorigenicity. High level of complexity within TICs niche was also confirmed by in vitro ATRA pretreatment which counteracted TICs enrichment after CDDP challenge differently in different compartments: increase of CD133 
